Better Subset Based on Trials Possible as Outcome, meeting most end-points
What if the Technosphere technology works fine, and each patient carries a backup insulin injection pen in the event of a failure, much like the Epi-Pens. This product may be approved for a subset of the population, and as more clinical evidence becomes known over 1-2 years of Phase IV studies, and further research, its customer base expands.
Maybe there is a way to meet the best of both worlds and reduce or refine the subset of the population that can use this insulin inhaler.
The share prices could then potentially hit $ 20.